Cargando…

Oral delivery of insulin with intelligent glucose-responsive switch for blood glucose regulation

BACKGROUND: The traditional treatment for diabetes usually requires frequent insulin injections to maintain normoglycemia, which is painful and difficult to achieve blood glucose control. RESULTS: To solve these problems, a non-invasive and painless oral delivery nanoparticle system with bioadhesive...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xia, Wu, Hongwei, Long, Ruimin, Wang, Shibin, Huang, Haiwang, Xia, Yanhua, Wang, Pei, Lei, Yifeng, Cai, Yuanyuan, Cai, Duanhua, Liu, Yuangang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362448/
https://www.ncbi.nlm.nih.gov/pubmed/32664978
http://dx.doi.org/10.1186/s12951-020-00652-z
Descripción
Sumario:BACKGROUND: The traditional treatment for diabetes usually requires frequent insulin injections to maintain normoglycemia, which is painful and difficult to achieve blood glucose control. RESULTS: To solve these problems, a non-invasive and painless oral delivery nanoparticle system with bioadhesive ability was developed by amphipathic 2-nitroimidazole–l-cysteine–alginate (NI–CYS–ALG) conjugates. Moreover, in order to enhance blood glucose regulation, an intelligent glucose-responsive switch in this nanoparticle system was achieved by loading with insulin and glucose oxidase (GOx) which could supply a stimulus-sensitive turnover strategy. In vitro tests illustrated that the insulin release behavior was switched “ON” in response to hyperglycemic state by GOx catalysis and “OFF” by normal glucose levels. Moreover, in vivo tests on type I diabetic rats, this system displayed a significant hypoglycemic effect, avoiding hyperglycemia and maintaining a normal range for up to 14 h after oral administration. CONCLUSION: The stimulus-sensitive turnover strategy with bioadhesive oral delivery mode indicates a potential for the development of synthetic GR-NPs for diabetes therapy, which may provide a rational design of proteins, low molecular drugs, as well as nucleic acids, for intelligent releasing via the oral route. [Image: see text]